Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Tango Therapeutics' Non Operating Income fell 5213.81% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 3986.31%. This contributed to the annual value of $15.5 million for FY2024, which is 2338.61% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Non Operating Income is $1.8 million, which was down 5213.81% from $2.1 million recorded in Q2 2025.
  • Tango Therapeutics' Non Operating Income's 5-year high stood at $4.4 million during Q1 2024, with a 5-year trough of -$81000.0 in Q4 2021.
  • Its 5-year average for Non Operating Income is $2.0 million, with a median of $2.1 million in 2025.
  • In the last 5 years, Tango Therapeutics' Non Operating Income crashed by 21095.89% in 2021 and then skyrocketed by 202345.68% in 2022.
  • Over the past 5 years, Tango Therapeutics' Non Operating Income (Quarter) stood at -$81000.0 in 2021, then soared by 2023.46% to $1.6 million in 2022, then surged by 175.8% to $4.3 million in 2023, then dropped by 23.46% to $3.3 million in 2024, then plummeted by 45.21% to $1.8 million in 2025.
  • Its Non Operating Income was $1.8 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.7 million in Q1 2025.